Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 8/20 | 0.68 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | MMP3 | P08254 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31398107 | 1.00 | HSD17B1 (0.68) | HSD17B1HSD17B2CYP3A4CYP2C9MMP3 | |
| SCHEMBL30165928 | 0.86 | HSD17B1 (0.58) | HSD17B1HSD17B2CYP3A4CYP2C9AR | |
| SCHEMBL1029016 | 0.86 | HSD17B1 (0.58) | HSD17B1HSD17B2CYP3A4CYP2C9AR | |
| SCHEMBL22507033 | 0.85 | MMP3 (0.56) | MMP3CA12CA2CA9ESR1 | |
| SCHEMBL12980799 | 0.84 | ESR1 (0.62) | HSD17B1HSD17B2CYP3A4CYP2C9MMP3 | |
| Phenol SCHEMBL28023068 | 0.83 | MMP3 (0.75) | HSD17B1HSD17B2MMP3CA12CA2 | |
| SCHEMBL7898375 | 0.82 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9CA12 | |
| SCHEMBL18411422 | 0.81 | TSHR (0.56) | MMP3CYP11B2CYP11B1ABCB1KAT6A | |
| SCHEMBL6067856 | 0.81 | MMP3 (0.71) | MMP3CA12CA2CA3CA6 | |
| SCHEMBL21189130 | 0.81 | CLK4 (0.57) | MMP3CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865472-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2024-06-12 | — | — | EP | disclosed |
| EP-3865472-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA Therapeutics Limited (IE) | 2021-08-18 | — | — | EP | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| EP-3310756-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2020-12-09 | — | — | EP | disclosed |
| US-10711196-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2019-11-07 | — | — | US | disclosed |
| US-10357504-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2019-07-23 | — | — | US | disclosed |
| US-10357504-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2019-07-23 | — | — | US | disclosed |
| US-10343982-B2 | Compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7259172-B2 | phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance | METHYLGENE INC. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-7259172-B2 | phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance | METHYLGENE INC. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-5262052-A | Separation of polycyclic aromatic hydrocarbons | BRIGHAM YOUNG UNIVERSITY (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966994-B2 | Thromboxane receptor antagonists | TBXA2R, TBXAS1, PTGIR | HSD17B1 2031/4885HSD17B2 1597/4885CYP3A4 1009/4885 |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ADA, ADAR, IMPDH1 | HSD17B1 362/4885HSD17B2 441/4885CYP3A4 311/4885 |
| US-10343982-B2 | Compounds and mesogenic media | MTX1, NEFM, MTX2 | HSD17B1 335/4885HSD17B2 416/4885CYP3A4 2194/4885 |
| US-10357504-B2 | Thromboxane receptor antagonists | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | MGAM, LSS, CYP51A1 | HSD17B1 115/4885HSD17B2 236/4885CYP3A4 449/4885 |
| US-10711196-B2 | Bimesogenic compounds and mesogenic media | BMP2, NEFM, MTX1 | HSD17B1 685/4885HSD17B2 649/4885CYP3A4 1690/4885 |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | HSD17B1 1363/4885HSD17B2 1275/4885CYP3A4 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.